Sexually transmitted infections

>

Latest News

FDA Accepts Priority Review of Gepotidacin for Oral Treatment of Uncomplicated Urogenital Gonorrhea / Image credit: ©MohamadFaisal/AdobeStock
FDA Accepts Gepotidacin for Priority Review for the Treatment of Uncomplicated Urogenital Gonorrhea

August 11th 2025

FDA accepts priority review of gepotidacin for uncomplicated urogenital gonorrhea, with phase 3 data showing non-inferiority to standard injectable therapy.

New Data at IAS 2025 Underscore Real-World Success of Long-Acting Injectable HIV Therapies / Image credit: ©Ezume Images/AdobeStock
New Data at IAS 2025 Underscore Real-World Success of Long-Acting Injectable HIV Therapies

July 8th 2025

Bacterial Vaginosis Recurrence Drops with Partner Treatment: Daily Dose / image credit: ©New Africa/AdobeStock
Bacterial Vaginosis Recurrence Drops with Partner Treatment: Daily Dose

April 28th 2025

Oral Gepotidacin Noninferior to Standard Therapy for Gonorrhea in Phase 3 Trial
Oral Gepotidacin Noninferior to Standard Therapy for Gonorrhea in Phase 3 Trial

April 15th 2025

Universal Syphilis Screening in the ED Outperforms Targeted Approaches: Daily Dose / image credit: ©New Africa/AdobeStock
Universal Syphilis Screening in the ED Outperforms Targeted Approaches: Daily Dose

April 4th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.